Malignant Pleural Mesothelioma, AdvancedNCT06031636
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
An observational study of Malignant Pleural Mesothelioma, Advanced, run by Tianjin Medical University Second Hospital at 1 site in China.
Trial summary
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Malignant Pleural Mesothelioma, Advanced
- What is being tested?
- Oncolytic Adenovirus H101 and Programmed death receptor-1 inhibitor
- Type of treatment
- Injection or infusion
- How many people
- 15 participants
- Where
- 1 siteChina
- Study dates
- 20 Jul 2023to 31 Jul 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with malignantpleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors.
Who may be able to join
- Age 18-75 years old (including boundary values), regardless of gender.
- Confirmed as late stage MPM patients who have failed immunotherapy.
- The patient or their legal representative can understand and sign the informed consent form.
- At least one lesion that can safely undergo intratumoral injection or intrapleural injection of oncolytic adenovirus as the target lesion, with a diameter of spiral CT ≥ 1cm or ordinary CT ≥ 2cm, and can be measured through imaging methods.
- ECOG score 0-2.
Who cannot join
- Physicians participating in the study believe that patients may not be able to provide continuous follow-up information.
- Any uncontrollable clinical problems (such as severe mental, neurological, cardiovascular, respiratory, and other systemic diseases).
- Contraindications to relevant drugs (such as oncolytic adenoviruses, PD-1 inhibitors, etc.)
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Tianjin Medical Unversity Second Hospital
Tianjin, Tianjin Municipality
Haitao Wang, Ph.D, +86-022-88326385, peterrock2000@126.com
Lili Wang, MM, +86-022-88326610, wangliliaigang@163.com
About this study
Official title: Observation of the Efficacy and Safety of Oncolytic Adenovirus Injection Combined With Programmed Death Receptor Inhibitors in Treatment of Advanced Malignant Pleural Mesothelioma : a Single Center, Prospective, Case Registration Study
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors.
Read the detailed description
By monitoring the clinical symptoms of patients with advanced immune resistant pleural mesothelioma treated with adenovirus injection combined with programmed death receptor (PD-1) inhibitors, we analyze and explore the effectiveness and safety of using oncolytic virus drugs. Exploring the influencing factors of using oncolytic adenovirus injection combined with PD-1 inhibitors to reverse immune resistance in MPM patients. Evaluate the safety of the drug, and finally evaluate the quality of life of patients using oncolytic adenovirus injection(H101) combined with PD-1 inhibitors.
- Conditions
- Malignant Pleural Mesothelioma, Advanced
- Being tested
- Oncolytic Adenovirus H101, Programmed death receptor-1 inhibitor
- Keywords
- Malignant Pleural Mesothelioma, Advanced, Oncolytic Adenovirus, Programmed Death Receptor
- Medical subject headings
- Mesothelioma, Malignant
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oncolytic Adenovirus H101Drug
Also called Recombinant Human Type-5 Adenovirus
The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
Programmed death receptor-1 inhibitorDrug
The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
| Study group | Role | What they receive |
|---|---|---|
| Oncolytic adenovirus(H101) combined with PD-1 inhibitors | This study observed 2-4 treatment cycles. For the convenience of statistics, this project stipulated that the first combined medication (v1) after the patient was enrolled in this study was administered with oncolytic virus (recombinant human adenovirus type 5) by intratumoral injection or intrapleural injection on the 1-3 days. On the 4th or 5th day, PD-1 injection was administered once per cycle. The completion of two visits in this study is considered a completed case, and subsequent treatment is determined jointly by the researcher and the subject. Receives: Drug: Oncolytic Adenovirus H101; Drug: Programmed death receptor-1 inhibitor |
What is being measured
The primary outcome is the main question the study is designed to answer.
ORR(Objective Response Rate)
The proportion of CR(complete response) and PR(partial response) in all patients.
Measured: 36 months
DCR(Disease Control Rate)
The proportion of CR(complete response), PR(partial response) and SD(stable disease) in all patients.
Measured: 36 months
Secondary outcomes (3)
PFS(Progression Free Survival)
Refers to the time from the first treatment day to the first occurrence of disease progression or death from any cause (whichever occurs first), and the end point event is determined by the investigator according to RECIST version1.1.
Measured: 36 months
OS(Overall Survival)
Time between the date of grouping and death from any cause or the end of the last follow-up visit.
Measured: 36 months
AEs(Adverse Events)
Toxicity were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. All serious and non-serious adverse events that occur after enrollment through 30 (+7) days after the last administration of H101 will be recorded.
Measured: 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2023
- Study start20 Jul 2023
- Primary completion31 Jul 2026 (estimated)
- Study completion31 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malignant Pleural Mesothelioma, AdvancedStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tianjin Medical University Second Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06031636
- Sponsor's protocol ID
- H101 for MPM
- Status last verified
- Sep 2023
- First submitted
- 2 Sep 2023
- Last updated
- 11 Sep 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided